Whalesbook
Wanbury Limited announced it will close its securities trading window starting April 1, 2026. This mandatory measure aligns with SEBI's (Prohibition of Insider Trading) Regulations, 2015, aiming to prevent insider trading before the company announces its audited financial results for the quarter and fiscal year ending March 31, 2026. The window is set to reopen 48 hours after these results are publicly declared. The closure is critical for maintaining market integrity and ensuring a level playing field by preventing individuals with access to non-public information from trading.
Established in 1988, Wanbury Limited is a prominent Indian pharmaceutical company. It specializes in Active Pharmaceutical Ingredients (APIs) and branded formulations, operating USFDA and EUGMP-approved manufacturing facilities. The company exports its products to over 50 countries and is recognized as a leading Indian manufacturer of Metformin HCl and a significant exporter of Tramadol.
Recently, Wanbury received approval from ANVISA Brazil for Sertraline Form II and a special grade of Metformin DC. Financially, the company reported a strong profit after tax of ₹44.4 crore for the nine months ending December 31, 2025, up from ₹10.3 crore year-on-year. While demonstrating growth, Wanbury has also navigated past regulatory scrutiny, including a 2017 SEBI order concerning disclosure lapses by a promoter entity and penalties from exchanges for earlier compliance issues.
During the closure, designated persons including directors, key managerial personnel, and employees are prohibited from trading in Wanbury's securities. This shifts their focus to ensuring timely and accurate financial reporting. Investors will be closely watching for the announcement of the Board Meeting date to approve the audited results for Q4 FY26 and the full fiscal year FY26. The detailed financial results, once declared, along with any management commentary, will be key indicators. Market sentiment may also be influenced by this upcoming performance data.
Wanbury operates within India's robust pharmaceutical sector alongside major players like Sun Pharmaceutical Industries, Divis Laboratories, Cipla, and Dr. Reddy's Laboratories. Like its peers, Wanbury contributes to India's strong global position in pharmaceuticals through API manufacturing, generic drugs, and branded formulations. Trading window closures are a standard practice across the industry, especially ahead of annual financial reporting.